Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026

PALISADE BIO, INC.

2026-Q1 EPS reported -$0.05

Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
R&D expense $6.4M in Q1 2026 vs $1.0M in Q1 2025 (+$5.4M) driven by PALI-2108 clinical and CMC costs.
G&A expense $4.4M in Q1 2026 vs $1.4M in Q1 2025 (+$3.0M) on higher employee costs and professional fees.
Completed Phase 1a/b for PALI-2108; Phase 1b FSCD cohort showed sustained exposure above IC90 and modulation of inflammatory/fibrotic pathways.
IND for Phase 2 UC expected 2Q 2026; Phase 2 UC trial start Q3 2026; Phase 2 CD trial start Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

PALISADE BIO, INC. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001357459-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.